Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal phase II Clinical Trial to Evaluate MB-207 in Previously Transplanted Patients with X-Linked Severe Combined Immunodeficiency (XSCID)

X
Trial Profile

A Pivotal phase II Clinical Trial to Evaluate MB-207 in Previously Transplanted Patients with X-Linked Severe Combined Immunodeficiency (XSCID)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MB 107 (Primary)
  • Indications Immunodeficiency disorders; X-linked genetic disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Mustang Bio
  • Most Recent Events

    • 11 Aug 2022 According to a Mustang Bio media release, the company expects to enroll the first patient in trial in 2023.
    • 27 Jul 2022 According to a Mustang Bio media release, this trial is expected to begin in the second half of 2022.
    • 23 Mar 2022 According to a Mustang Bio media release, in the second half of 2022 the company expects to enroll the first patient in Mustangs multicenter pivotal Phase 2 clinical trial to evaluate MB-107.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top